INSM•benzinga•
Lung Disease-Focused Insmed 'Is An Attractive Midcap Biotech,' Analyst Says
Summary
RBC Capital initiates Insmed with an Outperform rating, citing brensocatib's launch potential and Arikayce's growth. FDA decision on brensocatib due August 2025.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 25, 2025 by benzinga